Note: This article does not constitute any investment advice and recommendation, and is subject to official/company announcements; This article is only an introduction to health-related drugs, not a recommendation of treatment options (if involved), and does not represent the position of the platform. Any reproduction of articles requires permission.
Recently, Hetero announced a new partnership with Gilead Sciences Ireland UC (Gilead Sciences, NASDAQ: GILD). The parties entered into a non-exclusive, royalty-free, voluntary license agreement for the production and distribution of lenacapavir in 120 countries, primarily for low- and lower-middle-income countries (LMICs). The agreement will expand access to lenacapavir, an innovative HIV treatment in combination with other antiretroviral drugs, and will support HIV prevention through pre-exposure prophylaxis (PrEP).
Through this collaboration, we are taking an important step towards our goal of providing life-saving treatment options to HIV patients experiencing multiple treatment options and developing multiple drug resistance, while also bringing new hope for HIV prevention in areas with limited access to health care.” Lenacapavir is a breakthrough HIV-1 capsid inhibitor that can be used in combination with other antiretroviral drugs for the treatment of multidrug-resistant HIV-1 infection. Its unique mechanism of action enables multiple stages of the HIV life cycle to provide highly effective treatment options for patients with limited treatment options.
Increase access to affordable HIV treatment
Dr. Vamsi Krishna Bandi, Managing Director of Hetero Group of Companies, emphasized: “This collaboration with Gilead Sciences strengthens our determination to push the boundaries of HIV prevention and treatment. For more than 30 years, Hetero has been on the front lines of the global fight against HIV/AIDS, pioneering affordable, life-saving treatment options where they are needed most. We offer more than 30 combinations that address nearly 40%* of people living with HIV/AIDS worldwide, and we are incredibly proud of the positive results we’ve achieved so far. We will accelerate the introduction of lenacapavir in Africa, India, and other low- and middle-income countries, which have been central to our delivery of HIV/AIDS treatment. ”
With our strong focus on research, unrivalled scale of production, and expertise in distribution, we are fully positioned to rapidly expand access to lenacapavir in 120 high-incidence and resource-limited countries. He added that with our generic lenacapavir generic, we will expand our services to communities beyond our traditional reach, ensuring that even in the most under-resourced and remote areas, people have access to what they deserve.”
